Data for the paper: ‘Effects of different factors on the efficacy of anti PD-(L)1 monotherapy in patients with advanced non-small cell lung cancer: An observational, retrospective cohort study’

Effects of sex, age, EGFR mutation status and smoking status on immunotherapy. we showed that the benefits for PFS and OS were similar in male and female, and in younger (< 65 years of age) and older (≥65 years of age) patients. EGFR mutation status and smoking status are two independent influencing factors. Regardless of EGFR mutation status, the ORR and PFS of current-smokers were better than those of never-smokers; The benefits of immunotherapy for other mutant subtypes except 19del, L858R and T790M were similar to those of EGFR wild-type; Former-smokers are a unique population who benefit poor from immunotherapy than never-smokers or current-smokers.